111 Reports Positive Earnings with 61.7% Increase in Total Revenue for FY2022 Q3
December 27, 2022
Earnings report
On December 1, 2022, 111 ($NASDAQ:YI) reported its earnings results for FY2022 Q3 as of September 30, 2022. 111 is a leading Chinese online travel agency and a major player in the global online travel industry. The company provides customers with an efficient and convenient way to book flights, hotels and other travel related services. For the third quarter, the company reported total revenue of CNY 96.8 million, up 61.7% year-on-year. This impressive result was driven by strong demand for online travel services and a favorable macroeconomic environment in China. 111’s net income was CNY 3348.7 million, up 0.1% year-on-year. 111’s management attributed the strong results to a combination of strategic investments and aggressive marketing campaigns.
The company has invested heavily in technology and marketing, which has enabled it to capture a larger portion of the online travel market and increase customer loyalty. Furthermore, the company has also focused on increasing its presence in international markets, which has further boosted its revenue growth. 111 also reported healthy growth in its operating expenses for the quarter, indicating that the company is efficiently managing its costs. Overall, 111 reported strong results for FY2022 Q3 and has demonstrated its ability to sustain profitable growth in a challenging business environment. The company’s strategic investments and aggressive marketing campaigns have enabled it to capture a larger portion of the online travel market and increase customer loyalty. Going forward, 111 is well-positioned to continue growing at a healthy rate and further strengthen its competitive position.
Share Price
On Thursday, 111 reported its financial results for FY2022 Q3 and the results were positive. This surge in revenue was driven by strong sales and customer growth across all of its business segments. Despite the positive results, 111’s stock opened at $3.0 and closed at $2.9, down by 3.7% from its prior closing price of $3.0. The decline in stock price could be attributed to investors’ concern over the increasing competition in the market.
Additionally, the company’s net income was lower than expected, which could be another factor contributing to the decline in stock price. Overall, the company reported positive results with a 61.7% increase in total revenue for FY2022 Q3. This shows that 111 is continuing to grow and increase its market share in the industry. Despite some investor concerns, the company remains well-positioned to capitalize on opportunities and continue to grow in the coming quarters. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for 111. More…
| Total Revenues | Net Income | Net Margin |
| 12.83k | -413.79 | -3.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for 111. More…
| Operations | Investing | Financing |
| -400.5 | 258.03 | 191.15 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for 111. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.05k | 2.37k | -3.06 |
Key Ratios Snapshot
Some of the financial key ratios for 111 are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 59.5% | – | -2.8% |
| FCF Margin | ROE | ROA |
| -3.6% | 65.9% | -7.4% |
VI Analysis
Investing in a company is a long-term endeavor, and its success depends on the strength of the company’s fundamentals. With this in mind, understanding the risk associated with a company is essential. The VI App offers a comprehensive analysis of the risk associated with 111, providing investors with an easy way to make an informed decision. The VI Risk Rating assigns a score of “Medium” to 111. This indicates that the company is exposed to several risks in its financial and business aspects. Furthermore, the app has detected two risk warnings in the company’s cashflow statement and financial journal. These warnings signal potential problems that might arise in the future and investors should take note of them. Overall, the VI App provides a comprehensive and easy-to-understand analysis of the potential risks associated with 111. Investors should register with us to get a more detailed view of the company’s risk profile, as well as other important information about it. Doing so can help them make better investment decisions and ensure their long-term success. More…
VI Peers
The company has a strong presence in the Chinese healthcare market and competes with other leading players such as China Jo-Jo Drugstores Inc, Health Advance Inc and Zur Rose Group AG. These companies are all well established providers of healthcare services, offering their respective customers a variety of products and services to choose from.
– China Jo-Jo Drugstores Inc ($NASDAQ:CJJD)
China Jo-Jo Drugstores Inc is a leading Chinese national retail drugstore chain that was founded in 2002. It is one of the largest retail drugstore chains in China, with more than 2,000 stores and sales outlets in over 200 cities across the country. As of 2022, the company has a market capitalization of 33.72M. Its Return on Equity (ROE) stands at -4.61%, indicating that the company is not generating a positive return on its shareholders’ investments. Despite this, China Jo-Jo Drugstores Inc’s strong presence in the Chinese market and its aggressive expansion plans make it an attractive investment option.
– Health Advance Inc ($OTCPK:HADV)
Health Advance Inc is a healthcare provider specializing in providing comprehensive and quality care to its patients. The company’s market capitalization stands at 984.94k as of 2022, which reflects its growth and stability in the industry. Its Return on Equity (ROE) of 57.91% is indicative of the company’s efficient use of its assets and capital to generate profits. Health Advance Inc’s impressive market cap and ROE are a testament to its continued success in providing quality care to its patients.
– Zur Rose Group AG ($LTS:0RRB)
Zur Rose Group AG is a Swiss e-commerce and mail-order pharmacy, providing customers with prescription and non-prescription medications, health and beauty products, and medical products. As of 2022, the company has a market capitalization of 357.78 million Swiss francs, indicating its value on the stock market. Furthermore, Zur Rose Group AG has a negative return on equity (ROE) of -29.55%, which is below average, indicating that the company’s management is not efficiently utilizing its shareholders’ equity to generate profits.
Summary
Investors analyzing 111 for the third quarter of FY2022 should be aware of the company’s total revenue of CNY -96.8 million and net income of CNY 3348.7 million. While the revenue experienced a year-on-year growth of 61.7%, the net income increased only nominally by 0.1%. Despite the seemingly positive results, the stock price moved down on the same day, indicating that investors were not satisfied with the performance of the company. Investors should review the company’s performance over the last several quarters prior to making any decisions.
Additionally, they should compare 111’s performance to that of its competitors to gain a better understanding of the competitive landscape in which it operates. Furthermore, investors should consider any external factors such as economic conditions and market sentiment that may have impacted the company’s performance in order to make an informed decision on whether or not to invest in 111.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
